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We appreciate Drs Blower’s and Aapro’s comments to our paper.
The optimal design of the study obviously would have been to
cross-over in both directions, but the small size of the study and
its unsponsored nature did not allow for such design. We have
stated in our paper that our ﬁndings merely allow to conclude that
one 5HT3 receptor antagonist may be effective after another given
at the recommended dose and schedule fails. There is no reason to
believe that one 5HT3 receptor antagonist is better than another,
we have only demonstrated that granisetron may be helpful after
failure to ondansetron, like we have previously reported protection
with ondansetron after failure to tropisetron (de Boer et al, 1995),
which indicates in our opinion that there is no complete cross-
resistance between these compounds.
We disagree that psychological effects have played a role in
the successful cross-over in our study, as the study was
double-blinded and no such effects were observed in the ‘contin-
ued with ondansetron’ group; 1 complete protection with
continued use of ondansetron out of 21 patients, vs nine success-
ful cross-overs, of 19 patients on granisetron (complete
protection after previous acute-emesis protection failure on
ondansetron).
We have written a concise report on our observations and delib-
erately refrained from hypothetical explanations, but we do not
believe that scheduling or dosing of ondansetron may explain these
results. Ondansetron was administered as is considered standard
according to international consensus guidelines, which is a single
dose of 8 mg prior to the chemotherapy (Roila, 1998; Gralla et
al, 1999). Therefore we concluded that there is no complete cross
resistance between 5HT3 receptor antagonists, and that patients
who have acute emesis protection failure on one 5HT3 receptor
antagonist should be offered cross-over to another 5HT3 receptor
antagonist.
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